SEC Form 4 · accession 0001104659-18-006636
Ra Pharmaceuticals, Inc. · RARX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ramin Farzaneh-Far
Officer — Chief Medical Officer
Period of report
Feb 1, 2018
Accepted (ET)
Feb 5, 2018 · 9:46 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001481512
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $7.33 | Feb 1, 2018 | A | 62,500 | A | — | Feb 1, 2028 | Common Stock | 62,500 | 62,500 | D |
| Restricted Stock UnitF2,F3 | $0.00 | Feb 1, 2018 | A | 31,250 | A | — | — | Common Stock | 31,250 | 31,250 | D |
Explanation of responses
- F1These stock options vest in 48 equal monthly installments on each monthly anniversary thereafter following February 1, 2018, the grant date.
- F2These Restricted Stock Units vest in three equal installments on each of February 1, 2019, February 1, 2020, and February 1, 2021.
- F3Not applicable.